{"id":"doxorubicin-hydrochloride-liposome","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Mucositis"},{"rate":"30-50","effect":"Alopecia"},{"rate":"5-10","effect":"Cardiotoxicity (reduced vs. free doxorubicin)"},{"rate":"5-15","effect":"Infusion reactions"},{"rate":"10-30","effect":"Hand-foot syndrome"}]},"_chembl":{"chemblId":"CHEMBL1095057","moleculeType":"Small molecule","molecularWeight":"858.47"},"_dailymed":{"setId":"c8eb4784-36e0-483f-9e5d-af0552e49bb5","title":"DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [SAGENT PHARMACEUTICALS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxorubicin is an anthracycline chemotherapy drug that works by intercalating into double-stranded DNA and inhibiting topoisomerase II, leading to DNA strand breaks and cell death. The liposomal formulation encapsulates the drug in lipid nanoparticles, which preferentially accumulate in tumor tissues through the enhanced permeability and retention (EPR) effect, thereby increasing drug concentration at the tumor site while reducing exposure to healthy tissues and decreasing cardiotoxicity compared to free doxorubicin.","oneSentence":"Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:55.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Ovarian cancer"},{"name":"Multiple myeloma"},{"name":"Kaposi sarcoma"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT05210374","phase":"PHASE1","title":"Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2023-03-09","conditions":"Relapsed Sarcomas","enrollment":24},{"nctId":"NCT04092270","phase":"PHASE1","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-07","conditions":"Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":54},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT00379340","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-04-30","conditions":"Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor","enrollment":395},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT07362914","phase":"PHASE3","title":"Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-07","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07286240","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-11-15","conditions":"Treatment of Recurrent Ovarian Cancer","enrollment":40},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT04908787","phase":"PHASE3","title":"A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-06-11","conditions":"Ovarian Cancer","enrollment":421},{"nctId":"NCT00911183","phase":"PHASE2","title":"Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-12-02","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT05567601","phase":"PHASE1","title":"Doxil/Caelyx BE Study","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2023-12-16","conditions":"Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma","enrollment":36},{"nctId":"NCT05830539","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-03-10","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":68},{"nctId":"NCT01818063","phase":"PHASE2","title":"Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-04-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":9},{"nctId":"NCT05457829","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-30","conditions":"Rhabdomyosarcoma, Child","enrollment":88},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT02098343","phase":"PHASE1, PHASE2","title":"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2014-03","conditions":"Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53","enrollment":247},{"nctId":"NCT03268382","phase":"PHASE2","title":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2017-07-31","conditions":"High-grade Serous Ovarian Cancer","enrollment":36},{"nctId":"NCT06651866","phase":"PHASE1","title":"Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT02488564","phase":"PHASE2","title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2014-12-17","conditions":"HER-2 Positive Breast Cancer","enrollment":49},{"nctId":"NCT06753721","phase":"PHASE1, PHASE2","title":"An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-12-31","conditions":"Advanced Colorectal Adenocarcinoma","enrollment":13},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT06694324","phase":"PHASE2","title":"First-line Treatment of Advanced/unresectable DDLPS","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12-01","conditions":"Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)","enrollment":49},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT00004112","phase":"PHASE3","title":"Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1999-09-01","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT06600841","phase":"PHASE2","title":"Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-10-01","conditions":"Platinum-resistant Ovarian Cancer (PROC), Immunotherapy","enrollment":37},{"nctId":"NCT06475599","phase":"PHASE3","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-07","conditions":"Endometrial Cancer","enrollment":420},{"nctId":"NCT06412068","phase":"PHASE2","title":"A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-06-01","conditions":"Primary Mediastinal Large B Cell Lymphoma","enrollment":32},{"nctId":"NCT05926492","phase":"PHASE2","title":"A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-09","conditions":"Osteosarcoma","enrollment":160},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT00019630","phase":"PHASE1","title":"Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-07","conditions":"Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer","enrollment":""},{"nctId":"NCT00712881","phase":"PHASE2","title":"Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Cephalon, Inc.","startDate":"2008-10-13","conditions":"Breast Cancer","enrollment":126},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT04589741","phase":"PHASE2","title":"Toripalimab Combined With CAV/IE Regimen","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-10-23","conditions":"Soft Tissue Sarcoma","enrollment":200},{"nctId":"NCT04244552","phase":"PHASE1","title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","status":"TERMINATED","sponsor":"Atreca, Inc.","startDate":"2020-02-11","conditions":"Breast Cancer, Colorectal Cancer, Ovarian Cancer","enrollment":87},{"nctId":"NCT00657878","phase":"PHASE3","title":"Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2008-11","conditions":"Ovarian Cancer","enrollment":215},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT06098599","phase":"PHASE1","title":"Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2022-05-17","conditions":"Advanced Breast Cancer","enrollment":48},{"nctId":"NCT04172259","phase":"PHASE2","title":"ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-01-10","conditions":"Breast Cancer, Neoadjuvant Chemotherapy","enrollment":156},{"nctId":"NCT01177683","phase":"PHASE1, PHASE2","title":"Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma","status":"TERMINATED","sponsor":"Sherif Farag, MB, BS","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT00004197","phase":"PHASE2","title":"Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1999-06-25","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT05982756","phase":"PHASE1","title":"Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2020-01-01","conditions":"Bortezomib, Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT05887726","phase":"PHASE2","title":"Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT00003388","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-07-26","conditions":"Lymphoma","enrollment":38},{"nctId":"NCT05809180","phase":"NA","title":"Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-04","conditions":"Diffuse Large B Cell Lymphoma","enrollment":35},{"nctId":"NCT04852367","phase":"PHASE1","title":"PanDox: Targeted Doxorubicin in Pancreatic Tumours","status":"WITHDRAWN","sponsor":"University of Oxford","startDate":"2021-06-16","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV, Pancreatic Cancer Non-resectable","enrollment":""},{"nctId":"NCT02315196","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":62},{"nctId":"NCT05775705","phase":"PHASE3","title":"L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2023-08-01","conditions":"PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus","enrollment":25},{"nctId":"NCT05774275","phase":"PHASE1, PHASE2","title":"The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-08-25","conditions":"High-Risk Localized Soft Tissue Sarcoma","enrollment":52},{"nctId":"NCT05536102","phase":"PHASE2","title":"The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-09-05","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT05731258","phase":"","title":"Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Liposomal Doxorubicin, Efficacy","enrollment":150},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT00346125","phase":"NA","title":"PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-04-10","conditions":"Sarcoma","enrollment":70},{"nctId":"NCT01859819","phase":"PHASE2","title":"Treatment for Advanced B-Cell Lymphoma","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-01","conditions":"Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma","enrollment":45},{"nctId":"NCT05561036","phase":"PHASE3","title":"A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-09-29","conditions":"Desmoid Tumor","enrollment":72},{"nctId":"NCT01319981","phase":"PHASE2","title":"Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-03-05","conditions":"Leukemia","enrollment":31},{"nctId":"NCT01673217","phase":"PHASE1","title":"Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-04","conditions":"Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer","enrollment":18},{"nctId":"NCT03794778","phase":"PHASE4","title":"Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2019-03-19","conditions":"Efficacy and Safety","enrollment":396},{"nctId":"NCT04624984","phase":"PHASE2","title":"PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-01","conditions":"Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma","enrollment":42},{"nctId":"NCT05354076","phase":"PHASE2","title":"Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2000-03-01","conditions":"Advanced Malignant Tumors","enrollment":30},{"nctId":"NCT01026220","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-12-07","conditions":"Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma","enrollment":166},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT05315336","phase":"PHASE3","title":"L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2022-06-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":50},{"nctId":"NCT05302336","phase":"PHASE4","title":"AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapeutic Toxicity","enrollment":402},{"nctId":"NCT03983226","phase":"PHASE2","title":"Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)","status":"RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2019-10-18","conditions":"Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":167},{"nctId":"NCT05273944","phase":"PHASE1","title":"Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients","status":"UNKNOWN","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2021-07-28","conditions":"Breast Cancer, Ovarian Cancer","enrollment":80},{"nctId":"NCT05164978","phase":"NA","title":"DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-05-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":20},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT05164770","phase":"PHASE3","title":"Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-03-01","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma","enrollment":160},{"nctId":"NCT05097443","phase":"PHASE3","title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-04-15","conditions":"High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma","enrollment":130},{"nctId":"NCT05040555","phase":"NA","title":"R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","status":"RECRUITING","sponsor":"oubai, MD/PhD","startDate":"2021-08-30","conditions":"Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B","enrollment":64},{"nctId":"NCT05008666","phase":"PHASE2","title":"Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Safety and Efficacy","enrollment":37},{"nctId":"NCT05006469","phase":"PHASE3","title":"Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Liao Aijun","startDate":"2021-06-01","conditions":"Bendamustine, Multiple Myeloma","enrollment":10},{"nctId":"NCT04998760","phase":"PHASE2","title":"A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )","status":"UNKNOWN","sponsor":"Qi Zhou","startDate":"2021-08-03","conditions":"1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer","enrollment":96},{"nctId":"NCT04983550","phase":"PHASE2","title":"Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-09","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":126},{"nctId":"NCT03055143","phase":"PHASE1","title":"Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2008-09-03","conditions":"Breast Cancer and Ovarian Cancer","enrollment":29},{"nctId":"NCT04337632","phase":"PHASE3","title":"Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer","status":"UNKNOWN","sponsor":"Hunan Cancer Hospital","startDate":"2017-08-01","conditions":"Ovarian Cancer","enrollment":338},{"nctId":"NCT00296010","phase":"PHASE3","title":"Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2005-08","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT03749850","phase":"PHASE1","title":"Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2021-03","conditions":"Metastatic Breast Cancer, Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT00442260","phase":"PHASE1, PHASE2","title":"Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2007-02","conditions":"Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT04606108","phase":"PHASE2","title":"Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-19","conditions":"Soft Tissue Sarcoma","enrollment":62}],"_emaApprovals":[],"_faersSignals":[{"count":39,"reaction":"DRUG INEFFECTIVE"},{"count":37,"reaction":"FEBRILE NEUTROPENIA"},{"count":36,"reaction":"NAUSEA"},{"count":26,"reaction":"BONE MARROW FAILURE"},{"count":26,"reaction":"NEUTROPENIA"},{"count":20,"reaction":"MYELOSUPPRESSION"},{"count":19,"reaction":"DISEASE PROGRESSION"},{"count":19,"reaction":"VOMITING"},{"count":17,"reaction":"PANCYTOPENIA"},{"count":17,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Doxil","Caelyx®/Lipodox®","Doxorubicin Hydrochloride Liposomal injection 20 mg/10 mL","A","PLD"],"phase":"marketed","status":"active","brandName":"Doxorubicin hydrochloride liposome","genericName":"Doxorubicin hydrochloride liposome","companyName":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","companyId":"shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}